By


Palvella Therapeutics Reports Top-Line Results from Pivotal Phase 2/3 VALO Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel in Patients with Pachyonychia Congenita

~ VALO Study Misses Primary Endpoint in Phase 3 Randomized Withdrawal Portion ~
~ VALO Study Achieves Primary Endpoint in Phase 2 Open-Label Portion ~
~ Palvella Plans to Share Results with the U.S. Food and Drug Administration in the First Quarter of 2021 ~

See more here

By


Oncora Medical to power Mass General’s Pediatric Proton/Photon Consortium Registry to fight pediatric cancer with data

See more here

By


TiE Boston recognizes Purnanand Sarma, Ph.D. President & CEO of Immunome, as 2020 Lifetime Achievement Awardee

Dr. Sarma to be honored at the 2020 TiE Boston Gala, Keynote Fireside Chat with Kiran Mazumdar-Shaw, CMD of Biocon

See more here

By


ImmunoGenesis: Acquisition Strengthens “Cold” Tumor Targeting Pipeline

  • ImmunoGenesis acquires rights to evofosfamide; Phase 2 clinical testing in combination with checkpoint blockade is planned for 2021.
  • Evofosfamide is the only known reducer of solid tumor hypoxia, a driver of therapeutic resistance in immunologically “cold” tumors such as pancreatic & prostate cancer. 

See more here

By


Envara Health Named Winner of Rabobank’s FoodBytes! Pitch 2020 Competition

Advanced Nutrition Company Recognized in Food Tech Category with Award for Innovation in Clinical Nutrition

See more here

By


Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with
Major Depressive Disorder 

See more here

By


Venatorx Pharmaceuticals Names Robert Waltermire, Ph.D. Senior Vice President, CMC

See more here

By


Immunome Reports Third Quarter 2020 Financial Results and Significant Progress

– Completed $44.9M IPO in October –

– Identified COVID 19 Neutralizing antibodies –

– Significant progress made on lead programs, including IMM-BCP-01 for the treatment of COVID-19 in collaboration with US Department of Defense –

See more here

By


Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases

See more here